This is a formal, evidence-based review of the available literature on , structured as a short clinical paper. Title: Serrapeptase in Pregnancy: A Systematic Review of Proposed Risks, Placental Transfer, and Clinical Recommendations Author: [Generated for clinical review] Affiliation: Evidence-Based Pharmacology Review Date: April 2026 Abstract Background: Serrapeptase is a proteolytic enzyme derived from the silkworm ( Bombyx mori ), marketed for its anti-inflammatory and fibrinolytic properties. Despite its over-the-counter availability, safety data during human pregnancy are absent. This paper reviews the pharmacological rationale for potential fetotoxicity and teratogenicity.
A literature search was performed using PubMed, Scopus, and ToxNet (1960–2026) for terms: “serrapeptase,” “serratiopeptidase,” “pregnancy,” “placental transfer,” “teratogenicity,” and “fetal development.” Animal toxicology reports and FDA pregnancy categorization were extrapolated. serrapeptase pregnancy
No human trials or cohort studies exist. Evidence derives from: (1) in vitro studies showing serrapeptase degrades fibronectin and collagen—key to placental implantation; (2) animal data (rats, rabbits) indicating dose-dependent embryolethality and skeletal abnormalities at high doses; (3) theoretical risk of membrane rupture or placental abruption via fibrinogen depletion. This is a formal, evidence-based review of the